Drugs Containing Excipient (Inactive Ingredient) AZELAIC ACID

Generic drugs containing AZELAIC ACID excipient

Company	Ingredient	NDC	Excipient
Good Manager Holdings Inc	5% minoxidil hair serum	82372-008	AZELAIC ACID

Azelaic Acid Market Dynamics, Financial Trajectory, Patent Risk, and Pharmaceutical Supply Outlook

Last updated: September 17, 2026

Azelaic acid is an off-patent dicarboxylic acid used primarily as a dermatologic active ingredient, not as a conventional pharmaceutical excipient. Its commercial value comes from topical formulations for acne and rosacea, cosmetic products for hyperpigmentation, and differentiated delivery systems rather than from control of the underlying molecule. The market has low API barriers, intense generic and contract-manufacturing competition, and better margins in finished topical products than in bulk azelaic acid.

Financial growth is likely to remain moderate and fragmented. Volume demand should benefit from acne, rosacea, and cosmetic skin-brightening use, while pricing will remain constrained by low-cost Asian supply and generic substitution. The strongest commercial positions are in prescription formulations, high-purity grades, micronized material, foams, gels, creams, and branded cosmetic systems with documented tolerability.

What is azelaic acid, and is it an excipient or an active pharmaceutical ingredient?

Azelaic acid is a naturally occurring saturated nine-carbon dicarboxylic acid with the chemical formula C9H16O4. In approved dermatology products, it is the active pharmaceutical ingredient.

Attribute	Data
Chemical name	Nonanedioic acid
CAS number	123-99-9
Molecular formula	C9H16O4
Therapeutic role	Topical active ingredient
Main indications	Acne vulgaris and inflammatory rosacea
Common strengths	15% and 20%
Dosage forms	Foam, gel, cream, lotion, and cosmetic serum
Regulatory status	FDA-approved topical drug ingredient
Primary commercial markets	United States, Europe, Asia-Pacific, and global cosmetics

Azelaic acid can technically be used as a formulation component in non-drug products, but it is not generally classified as an inactive excipient in the FDA’s finished prescription products. In Finacea and Azelex, the ingredient is the therapeutic agent. The formulation excipients include solvents, emulsifiers, preservatives, propellants, polymers, and skin-conditioning agents.

This distinction affects market analysis. Bulk azelaic acid competes as a chemical and pharmaceutical raw material, while the higher-value segment is based on formulation technology, regulatory documentation, manufacturing quality, and brand recognition.

How large is the azelaic acid pharmaceutical and cosmetic market?

Public companies rarely report azelaic acid revenue separately. Market estimates are therefore usually based on commercial research models rather than audited company disclosures. The relevant market has three overlapping segments:

1. Pharmaceutical-grade API.
2. Prescription and over-the-counter topical products.
3. Cosmetic and cosmeceutical products.

The cosmetic segment is larger in product count and broader in geographic reach. The pharmaceutical segment has higher regulatory barriers but lower unit volumes. Prescription products generally generate higher revenue per gram because they incorporate clinical development, regulatory compliance, pharmacy distribution, and branded marketing.

Segment	Demand driver	Pricing profile	Competitive intensity
Bulk technical azelaic acid	Cosmetics, industrial applications	Low	High
Pharmaceutical-grade API	Topical drug manufacturing	Low to moderate	High
Generic creams and gels	Prescription substitution	Moderate	Very high
Branded dermatology products	Physician and consumer loyalty	High	Moderate
Cosmetic serums and creams	Hyperpigmentation and acne claims	Moderate to high	High
Advanced delivery systems	Foams, emulsions, encapsulated products	Highest	Lower

Demand growth is supported by three factors. Acne is a large global dermatology category, rosacea has limited topical treatment options, and cosmetic users increasingly seek ingredients with established dermatology histories. Demand is constrained by the low cost of alternatives, including benzoyl peroxide, salicylic acid, retinoids, niacinamide, kojic acid, and hydroquinone in relevant markets.

The financial trajectory is therefore likely to separate by product type. Bulk API revenue should track volume and remain price-sensitive. Finished products with differentiated delivery and strong consumer positioning have better margin resilience.

What are the main commercial uses of azelaic acid?

Prescription acne products

Azelaic acid 20% cream has been used for mild-to-moderate inflammatory and comedonal acne. Its commercial advantages include low systemic exposure and suitability for patients who do not tolerate retinoids or benzoyl peroxide.

Azelex, a 20% azelaic acid cream, was approved by the FDA in 1995. Its long market history means that the active ingredient and basic cream concept have little remaining exclusivity value. Commercial performance depends on generic availability, payer coverage, physician familiarity, and retail distribution.

Prescription rosacea products

Finacea 15% gel and Finacea 15% foam are used for inflammatory papules and pustules associated with rosacea. The foam format has greater formulation value because it addresses spreadability, cosmetic acceptability, and patient adherence.

The foam product illustrates the central economics of the market: azelaic acid itself is inexpensive, but formulation development and regulatory approval can support higher product-level pricing.

Cosmetic and cosmeceutical products

Cosmetic azelaic acid products are marketed for uneven skin tone, post-inflammatory hyperpigmentation, acne-prone skin, and redness. These products are sold through dermatology clinics, pharmacies, e-commerce platforms, and specialty beauty retailers.

Cosmetic demand can expand faster than prescription demand, but the segment has weaker pricing discipline and more variable product quality. Concentration, particle size, suspension stability, packaging, and claims compliance determine product differentiation.

What patents protect azelaic acid products?

The core azelaic acid molecule is off-patent. No commercially meaningful composition-of-matter exclusivity remains for the active ingredient.

Patent protection has historically focused on:

• Topical compositions.
• Foam systems.
• Gel and emulsion vehicles.
• Particle-size control.
• Solubilization and dispersion.
• Manufacturing methods.
• Specific treatment regimens.
• Combination products.
• Packaging and delivery systems.

The practical patent estate is product-specific rather than molecule-wide.

Protection category	Commercial relevance	Current risk profile
Azelaic acid molecule	Low; off-patent	No meaningful core-molecule barrier
20% cream	Limited	Generic substitution established
15% gel	Moderate	Formulation and method claims may matter
15% foam	Higher	Delivery-system patents can delay direct substitution
Cosmetic serum	Variable	Usually protected by branding and trade dress
Manufacturing process	Moderate	Relevant to quality and cost, rarely blocks all supply
Method of use	Limited to moderate	Scope depends on claim language and jurisdiction

Patents associated with branded azelaic acid products may have expired, been challenged, or become commercially less important as generic alternatives entered the market. A current freedom-to-operate determination requires review of live claims in the relevant jurisdiction, prosecution history, terminal disclaimers, and Orange Book-listed patents.

What is the Orange Book status of azelaic acid products?

The FDA Orange Book has historically listed approved azelaic acid products including Azelex cream and Finacea gel or foam products. Orange Book status is product-specific and does not establish protection for bulk azelaic acid.

The key regulatory points are:

• Azelex 20% cream was approved under NDA 019839 in 1995.
• Finacea 15% gel was approved under NDA 020428 in 2002.
• Finacea 15% foam was approved under NDA 208470 in 2015.
• Generic applicants can rely on the relevant reference-listed drug through the abbreviated new drug application pathway.
• Orange Book-listed patents, if any remain relevant, govern only the listed product claims and expiration dates.

A Paragraph IV certification may challenge a listed patent before expiration. Because azelaic acid has an established history of generic competition, the central regulatory risk is usually abbreviated approval and substitution rather than a new chemical entity exclusivity dispute.

When does azelaic acid lose exclusivity?

The active ingredient has already lost core exclusivity. The relevant commercial question is when each formulation or method patent expires.

Exclusivity type	Position
New chemical entity exclusivity	Not relevant to the current market
Core composition-of-matter patent	Expired or unavailable
Azelex basic cream protection	Commercially expired
Finacea gel protection	Historic product-specific protection; generic competition exists
Finacea foam protection	Formulation and delivery claims may have had later expiry dates
Pediatric exclusivity	Must be checked against the specific FDA record
Orphan exclusivity	Not applicable
Regulatory exclusivity for bulk API	None

For investors and manufacturers, formulation patent expiration can matter more than active-ingredient exclusivity. A generic company may enter with a legally distinct cream, gel, or foam even while a branded formulation patent remains in force, provided it does not infringe valid claims.

Which companies compete in the azelaic acid market?

Competition exists at several levels.

Branded pharmaceutical companies

Historical branded products include:

• Almirall and associated dermatology businesses for Azelex-related commercial activity.
• Leo Pharma for Finacea-related products in key markets.
• Regional licensees and dermatology companies distributing azelaic acid products outside the United States.

Ownership and commercialization rights have changed across markets. Product-level revenue is usually not separately disclosed.

Generic manufacturers

Generic topical manufacturers compete through:

• 15% gel products.
• 20% cream products.
• Contract-manufactured lotions and emulsions.
• Pharmacy and online private-label products.

The generic market is fragmented because topical products are harder to replicate than oral tablets. The difficulty is not the active ingredient. It is achieving comparable viscosity, spreadability, particle distribution, pH, stability, preservative performance, and skin feel.

Cosmetic manufacturers

Cosmetic competition includes dermatology brands, pharmacy brands, direct-to-consumer companies, and private-label manufacturers. Many products use lower concentrations or different labeling claims than prescription medicines.

How strong is the azelaic acid patent estate?

The patent estate is weak at the molecule level and stronger at the formulation level.

A commercial strength assessment is:

Patent layer	Strength	Reason
Active ingredient	Low	Long-established and widely available
Standard cream	Low	Mature technology and generic precedent
Standard gel	Low to moderate	Some formulation complexity
Foam delivery	Moderate	More difficult vehicle and performance requirements
Encapsulation or controlled release	Moderate	Potentially differentiated but design-around risk remains
Combination products	Moderate	Claims depend on ingredients and treatment method
Manufacturing process	Moderate	Can protect yield, purity, or particle characteristics
Cosmetic claims	Low legally, high commercially	Branding often matters more than patent protection

The strongest barriers are manufacturing know-how, quality systems, regulatory files, and customer relationships. These barriers can support supply contracts even when patent protection is limited.

What manufacturing and supply-chain barriers affect azelaic acid?

Azelaic acid can be produced through chemical oxidation routes from oleic acid or related feedstocks. Commercial supply depends on feedstock cost, oxidation efficiency, purification, crystallization, particle-size control, and compliance with pharmaceutical quality standards.

Pharmaceutical buyers typically require:

• Defined impurity limits.
• Consistent assay and water content.
• Controlled particle-size distribution.
• Residual solvent testing.
• Microbial limits appropriate to the dosage form.
• GMP documentation.
• Audit support and change-control procedures.
• Stability data.
• Reliable batch-to-batch supply.

Cosmetic-grade supply can be less expensive but may not meet the documentation and impurity requirements needed for an approved drug product. This creates a quality-based barrier even where chemical production is technically straightforward.

The most important manufacturing advantage is often the ability to provide consistent micronized or finely dispersed material. Azelaic acid has limited water solubility, so particle engineering and vehicle selection influence product performance.

What generic entry risks exist for azelaic acid products?

Generic entry risk is high for conventional creams and gels. The active ingredient is inexpensive, the clinical history is long, and multiple suppliers can support manufacturing.

Risk is lower for:

• Foam products requiring specialized propellant systems.
• Products with complex emulsion architectures.
• Formulations using unusual particle-size specifications.
• Products supported by device or container-closure claims.
• Combination products with clinical differentiation.

Potential generic launch scenarios include:

Scenario	Likely effect
One generic cream enters	Moderate price erosion
Several generic creams enter	Significant price compression
Generic gel enters	Greater substitution across dermatology channels
Foam generic enters	Pressure on branded premium pricing
Cosmetic private-label expansion	Retail price compression and volume growth
New branded formulation launches	Segment fragmentation rather than molecule-level protection

Topical generic approval can take longer than simple oral-solid approval because equivalence depends on formulation performance. That delay can preserve branded revenue temporarily, but it does not create durable protection for the active ingredient.

What is the FDA regulatory status of azelaic acid?

Azelaic acid is an FDA-approved active ingredient in prescription topical dermatology products. The principal approved strengths are 15% and 20%, depending on the product and indication.

The regulatory environment has four commercial implications:

1. The ingredient has an established safety and efficacy history.
2. New entrants can rely on existing clinical knowledge.
3. Novel formulations may require comparative performance and product-specific evidence.
4. Cosmetic products cannot make drug claims without triggering drug-regulation risks.

A cosmetic product marketed for general skin appearance has a different regulatory pathway from a product claiming to treat acne, rosacea, or hyperpigmentation as a disease. Claim language, labeling, formulation, and distribution channel determine regulatory exposure.

How does azelaic acid compare with competing dermatology ingredients?

Ingredient	Main use	Relative cost	Differentiation
Azelaic acid	Acne, rosacea, pigmentation	Moderate	Broad dermatology profile
Benzoyl peroxide	Acne	Low	Strong antimicrobial and keratolytic positioning
Salicylic acid	Acne and exfoliation	Low	Mature OTC market
Tretinoin and other retinoids	Acne, photoaging	Moderate	Strong efficacy, greater irritation risk
Niacinamide	Barrier support and pigmentation	Low	Strong cosmetic adoption
Hydroquinone	Pigmentation	Low to moderate	Regulatory restrictions in some markets
Ivermectin	Rosacea	Higher	Prescription differentiation
Metronidazole	Rosacea	Low to moderate	Established generic competition

Azelaic acid has a favorable positioning for patients seeking a single topical ingredient with acne, redness, and pigmentation relevance. Its weakness is slower visible results in some cosmetic applications and potential irritation at higher concentrations.

What is the financial trajectory for azelaic acid?

The likely financial trajectory is volume growth with price pressure.

Near-term outlook

Prescription revenue should remain stable to modestly growing in markets where branded foam products retain physician or patient preference. Generic creams and gels will continue to limit pricing power.

Cosmetic revenue has stronger volume potential, driven by direct-to-consumer education, skin-care routines, and demand for multi-benefit ingredients. Margins will depend on branding, concentration, packaging, and claims support.

Medium-term outlook

The market is likely to divide into two tiers:

• Commodity API and generic topical products with low margins.
• Branded, formulation-led products with higher margins.

Suppliers with vertically integrated manufacturing, GMP certification, and reliable particle engineering should retain share even without strong patent protection. Companies dependent only on bulk material sales face greater price competition.

Revenue exposure by business model

Business model	Revenue outlook	Margin outlook
Bulk API supplier	Volume-driven	Low
GMP pharmaceutical API supplier	Stable to moderate growth	Moderate
Generic finished-dose manufacturer	Competitive growth	Low to moderate
Branded prescription product owner	Stable, formulation-dependent	Moderate to high
Cosmetic brand	Higher growth potential	Variable to high
Contract developer or manufacturer	Moderate	Moderate

What patent litigation and settlement risks affect the market?

Azelaic acid has lower litigation intensity than newer dermatology drugs because the active ingredient is mature and generic entry is established. The principal disputes would concern formulation patents, abbreviated application certifications, trade secrets, manufacturing processes, or product-specific regulatory exclusivity.

Settlement agreements can delay a generic launch, but their economic value depends on the remaining patent term and the number of alternative formulations. A settlement covering one foam or gel does not necessarily block a competing cream or cosmetic product.

The most material diligence points are:

• Current Orange Book listings.
• Patent expiration and terminal-disclaimer dates.
• Paragraph IV litigation under the Hatch-Waxman framework.
• Any authorized generic arrangements.
• Product-specific licensing rights.
• Regional commercialization agreements.
• Formulation patent claim scope.
• Regulatory exclusivity attached to the reference product.

Key Takeaways

• Azelaic acid is primarily an active pharmaceutical ingredient, not a conventional excipient.
• The molecule is off-patent, and bulk supply has low entry barriers.
• Commercial value is concentrated in finished formulations, especially foams, gels, and branded cosmetic systems.
• Generic risk is high for standard 20% creams and 15% gels.
• Formulation complexity, particle engineering, GMP capability, and regulatory documentation are stronger barriers than molecule-level patents.
• Prescription revenue is likely to remain stable but price-sensitive.
• Cosmetic demand offers greater volume growth but faces intense brand and private-label competition.
• The strongest financial positions belong to companies controlling differentiated delivery systems, trusted dermatology brands, or compliant pharmaceutical-grade supply.

FAQs about azelaic acid market economics and intellectual property

Is pharmaceutical-grade azelaic acid more valuable than cosmetic-grade azelaic acid?

Yes. Pharmaceutical-grade material requires tighter impurity controls, validated manufacturing, GMP documentation, and change-control procedures. It commands a premium over technical or cosmetic grades.

Can a company patent a new azelaic acid cream?

A company may patent a novel composition, delivery system, particle-size profile, manufacturing method, or treatment regimen. A patent on azelaic acid itself is not available as a practical matter.

Are azelaic acid cosmetic products subject to FDA approval?

Cosmetic products generally do not require premarket FDA approval, but products making acne or rosacea treatment claims can be regulated as drugs. Manufacturing, labeling, and claims must match the applicable regulatory category.

Does a generic azelaic acid product automatically substitute for Finacea foam?

No. Substitution depends on the specific approved product, pharmacy rules, payer policies, dosage form, and whether the generic is therapeutically and legally substitutable for the branded reference product.

What is the most attractive investment segment in azelaic acid?

Formulation-led dermatology products and compliant pharmaceutical-grade supply are more attractive than undifferentiated bulk API. Foams, stable emulsions, micronized systems, and branded cosmetic products offer greater pricing protection.

References

1. U.S. Food and Drug Administration. (1995). Azelex (azelaic acid) cream, 20%: Prescribing information and approval history. FDA.

2. U.S. Food and Drug Administration. (2002). Finacea (azelaic acid) gel, 15%: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2015). Finacea (azelaic acid) foam, 15%: Prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

7. National Center for Biotechnology Information. (2024). PubChem compound summary: Azelaic acid. U.S. National Library of Medicine.

8. American Academy of Dermatology. (2024). Acne and rosacea treatment guidelines. American Academy of Dermatology.